

Michael S. Budwick (admitted *pro hac vice*)  
Daniel N. Gonzalez (admitted *pro hac vice*)  
Meaghan Murphy (admitted *pro hac vice*)  
Shira A. Baratz (admitted *pro hac vice*)  
**MELAND BUDWICK, P.A.**  
3200 Southeast Financial Center  
200 South Biscayne Blvd.  
Miami, Florida 33131  
Telephone: (305) 358-6363  
Email: mbudwick@melandbudwick.com  
dgonzalez@melandbudwick.com  
mmurphy@melandbudwick.com  
sbaratz@melandbudwick.com

*Counsel for the Official Unsecured  
Creditors' Committee*

Davor Rukavina (TX Bar No. 24030781)  
Thomas D. Berghman (TX Bar No. 24082683)  
Garrick C. Smith (TX Bar No. 24088435)  
**MUNSCH HARDT KOPF & HARR, P.C.**  
500 N. Akard Street, Suite 4000  
Dallas, Texas 75201  
Telephone: (214) 855-7500  
Email: drukavina@munsch.com  
tberghman@munsch.com  
gsmith@munsch.com

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*,<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**COVER SHEET  
FOR THE THIRD MONTHLY FEE STATEMENT OF  
MUNSCH HARDT KOPF & HARR, P.C. FOR ALLOWANCE OF  
COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE  
PERIOD FROM AUGUST 1, 2024 THROUGH AND INCLUDING AUGUST 31, 2024**

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Ave., Dallas, Texas 75201.



248004024091000000000002

<b>Name of Applicant:</b>	Munsch Hardt Kopf & Harr, P.C.
<b>Authorized to Provide Professional Services to:</b>	Co-Counsel to the Official Committee of Unsecured Creditors
<b>Date of Retention:</b>	June 14, 2024, by order entered on July 26, 2024, at Dkt. No. 451
<b>Period for which Compensation and Reimbursement is Sought:</b>	August 1, 2024 through and including August 31, 2024
<b>Amount of Compensation Sought as Actual, Reasonable and Necessary:</b>	\$21,520.00 (80% of \$26,900.00)
<b>Amount of Expense Reimbursement Sought as Actual, Reasonable and Necessary:</b>	\$0.00
<b>Total Compensation and Expenses Requested in this Fee Statement (exclusive of 20% holdback):</b>	\$21,520.00

This is a:     monthly     interim     final application.

This is MHKH's third monthly fee statement.

**PRIOR MONTHLY FEE STATEMENTS**

Period Covered	Requested		Payments Received		Outstanding	
	Fees (\$)	Expenses (\$)	Fees (\$)	Expenses (\$)	Fees (\$)	Expenses (\$)
06/14/2024-06/30/2024	\$20,102.40 (80% of \$25,128.00)	\$400.00	\$20,502.40	\$400.00	\$5,025.60	\$0.00
07/01/2024-07/31/2024	\$18,166.80 (80% of \$22,708.50)	\$0.00	\$18,166.80	\$0.00	\$4,541.70	\$0.00

Michael S. Budwick (admitted *pro hac vice*)  
Daniel N. Gonzalez (admitted *pro hac vice*)  
Meaghan Murphy (admitted *pro hac vice*)  
Shira A. Baratz (admitted *pro hac vice*)

**MELAND BUDWICK, P.A.**  
3200 Southeast Financial Center  
200 South Biscayne Blvd.  
Miami, Florida 33131  
Telephone: (305) 358-6363  
Email: mbudwick@melandbudwick.com  
dgonzalez@melandbudwick.com  
mmurphy@melandbudwick.com  
sbaratz@melandbudwick.com

*Counsel for the Official Unsecured  
Creditors' Committee*

Davor Rukavina (TX Bar No. 24030781)  
Thomas D. Berghman (TX Bar No. 24082683)  
Garrick C. Smith (TX Bar No. 24088435)  
**MUNSCH HARDT KOPF & HARR, P.C.**  
500 N. Akard Street, Suite 4000  
Dallas, Texas 75201  
Telephone: (214) 855-7500  
Email: drukavina@munsch.com  
tberghman@munsch.com  
gsmith@munsch.com

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*,<sup>2</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**THIRD MONTHLY FEE STATEMENT  
OF MUNSCH HARDT KOPF & HARR, P.C. FOR ALLOWANCE OF  
COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE  
PERIOD FROM AUGUST 1, 2024 THROUGH AND INCLUDING AUGUST 31, 2024**

Pursuant to sections 330 and 331 of title 11 of the United States Code (the “*Bankruptcy Code*”), rule 2016 of the Federal Rules of Bankruptcy Procedure (the “*Bankruptcy Rules*”), rule 2016-1 of the Local Bankruptcy Rules of the United States Bankruptcy Court for the Northern District of Texas (the “*Local Rules*”), and this Court’s *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for*

---

<sup>2</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Ave., Dallas, Texas 75201.

*Retained Professionals*, entered on May 13, 2024 [Dkt No. 259] (the “*Interim Compensation Procedures Order*”), Munsch Hardt Kopf & Harr, P.C. (“*MHKH*”), attorneys for the Official Committee of Unsecured Creditors (the “*Committee*”) in the above-captioned chapter 11 cases, hereby submits its second monthly fee statement (this “*Monthly Fee Statement*”) for interim allowance and (a) payment of compensation for professional services to the Committee during the period from August 1, 2024 through and including August 31, 2024 (the “*Fee Period*”) in the amount of \$21,520.00 representing 80% of the \$26,900.00 of fees owed to MHKH for professional services to the Committee during the Fee Period and (b) reimbursement of 100% of the actual and necessary expenses incurred by MHKH during the Fee Period in connection with such services in the amount of \$0.00. In support of this Application, MHKH respectfully represents as follows:

### **BACKGROUND**

1. On April 1, 2024 (the “*Petition Date*”), each Debtor filed a voluntary petition under chapter 11 of the United States Bankruptcy Code. Since the Petition Date, the Debtors have been operating their business and managing their property as debtors in possession pursuant to 11 U.S.C. §§ 1107(a) and 1108, no trustee or examiner has been sought or appointed. The Cases have been consolidated for procedural purposes only and are being jointly administered.

2. On June 10, 2024, the United States Trustee appointed the Committee [Dkt. No. 322]. The Committee’s members are: (1) Connor Group Global Services, LLC; (2) Biorasi, LLC; and (3) Monica Gangal. Brian Chaiken, Esq. of Biorasi, LLC was subsequently selected as Chairperson of the Committee.

3. On June 14, 2024, the Committee selected Meland Budwick, P.A. to serve as its lead counsel, and MHKH to serve as co-counsel and local counsel.

4. On May 13, 2024, this Court entered the Interim Compensation Procedures Order [Dkt No. 259], authorizing certain estate professionals (“**Professionals**”) to submit monthly applications for interim compensation and reimbursement for expenses, pursuant to procedures specified therein. If no objections are made within ten (10) days after service of a monthly fee statement (the “**Objection Deadline**”), the Debtors are authorized to pay the Professional eighty percent (80%) of the requested fees and one hundred percent (100%) of the requested expenses. All fees and expenses paid are on an interim basis until final allowance by the Court.

5. The Committee retained MHKH as its co-counsel effective as of the June 14, 2024, pursuant to the *Order Authorizing and Approving the Employment of Munsch Hardt Kopf & Harr, P.C. as Co-Counsel for the Official Committee of Unsecured Creditors* [Dkt. No. 451] (the “**Retention Order**”). The Retention Order authorizes the Debtors’ estates to compensate and reimburse MHKH subject to allowance of such compensation and reimbursement by the Court.

6. In support of the Monthly Fee Statement, MHKH submits the following exhibits, which are attached hereto:

a) **Exhibit A** is a schedule of hours billed by MHKH attorneys and paraprofessionals during the Fee Period. MHKH attorneys expended a total of 51.7 hours in connection with these chapter 11 cases during the Fee Period. All services for which MHKH is requesting compensation were performed for or on behalf of the Committee.

b) **Exhibit B** is a schedule of the number of hours expended and fees incurred (on an aggregate basis) by MHKH attorneys and paraprofessionals during the Fee Period with respect to each of the subject matter categories MHKH established in accordance with its internal billing procedures.

c) **Exhibit C** is a detailed statement of the time expended and compensation earned as well as MHKH’s out-of-pocket expenses during the Fee Period.

**FEES AND EXPENSES**

7. MHKH has continuously rendered services to the Committee during the Fee Period, totaling 51.7 hours of professional services. The services of MHKH are necessary to enable the Committee to execute faithfully its duties. MHKH has provided, and will continue to provide, to the extent necessary, services to the Committee including the following:

- a) To give advice to the Committee with respect to its rights, powers and duties as the Committee in these Cases;
- b) To assist and advise the Committee in its consultations with the Debtors relative to the administration of these Cases;
- c) To assist with the Committee's investigation of the acts, conduct, assets, liabilities, and financial condition of the Debtors and of the operation of the Debtors' business and any other matters relevant to these Cases;
- d) To assist the Committee in its analysis of and negotiations with the Debtors or any third-party concerning matters related to, among other things, the terms of sales, a plan of reorganization or liquidation, or other conclusion of these Cases;
- e) To assist the Committee in requesting the appointment of a trustee or examiner, should such action become necessary;
- f) To represent the Committee at all hearings and other proceedings;
- g) To review and analyze all applications, orders, statements of operations and schedules filed with the Court and advise the Committee accordingly;
- h) To assist the Committee in preparing agreements, motions, applications, orders, complaints, answers, briefs and pleadings as may be necessary in furtherance of the Committee's interests and objectives; and
- i) To perform such other legal services as may be required under the circumstances of these Cases and are deemed to be in the interests of the Committee in accordance with the Committee's powers and duties as set forth in the Bankruptcy Code.

8. The total sum due to MHKH for professional services rendered on behalf of the Committee for the Fee Period is \$26,900.00, of which 80% will be due and payable immediately upon expiration of the Objection Deadline. MHKH submits that the professional services it

rendered on behalf of the Committee during this time were reasonable and necessary under the circumstances.

9. MHKH also expended costs on behalf of the Committee during the Fee Period in the sum of \$0.00, of which 100% will be due and payable immediately upon expiration of the Objection Deadline.

10. Although MHKH has made every effort to include all fees and expenses incurred during the Fee Period in this Monthly Fee Statement, some fees and expenses might have been omitted from this Monthly Fee Statement due to delays caused by accounting and processing during the Fee Period. MHKH reserves the right to submit further applications to the Court for allowance of such fees and expenses not included herein. Subsequent monthly fee statements and/or fee applications will be filed in accordance with the requirements of the Bankruptcy Code, the Bankruptcy Rules, the Local Rules, and the Interim Compensation Procedures Order.

WHEREFORE, MHKH requests (a) interim allowance and payment of compensation for professional services to the Committee during the Fee Period in the amount of \$21,520.00, representing 80% of the \$26,900.00 of fees owed to MHKH for professional services to the Committee during the Fee Period, and (b) reimbursement of 100% of the actual and necessary expenses incurred by MHKH during the Fee Period in connection with such services in the amount of \$0.00, for a total interim award amount of \$21,520.00.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]



Dated: September 10, 2024

Respectfully submitted,

By: /s/ Garrick C. Smith

Davor Rukavina (TX Bar No. 24030781)  
Thomas D. Berghman (TX Bar No. 24082683)  
Garrick C. Smith (TX Bar No. 24088435)  
**MUNSCH HARDT KOPF & HARR, P.C.**  
500 N. Akard Street, Suite 4000  
Dallas, Texas 75201  
Telephone: (214) 855-7500  
Email: drukavina@munsch.com  
tberghman@munsch.com  
gsmith@munsch.com

-and-

Michael S. Budwick (admitted *pro hac vice*)  
Daniel N. Gonzalez (admitted *pro hac vice*)  
Meaghan Murphy (admitted *pro hac vice*)  
Shira A. Baratz (admitted *pro hac vice*)  
**MELAND BUDWICK, P.A.**  
3200 Southeast Financial Center  
200 South Biscayne Blvd.  
Miami, Florida 33131  
Telephone: (305) 358-6363  
Email: mbudwick@melanbudwick.com  
dgonzalez@melanbudwick.com  
mmurphy@melanbudwick.com  
sbaratz@melanbudwick.com

***Counsel for the Official Unsecured Creditors'  
Committee***

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that, on September 10, 2024, a true and correct copy of the foregoing document was served via ECF notification on all parties entitled to ECF notification in these cases.

*/s/ Garrick C. Smith*

\_\_\_\_\_  
Garrick C. Smith

**EXHIBIT A**

**Summary of Hours Billed by MHKH Timekeepers for the Fee Period**

<b>Name</b>	<b>Position</b>	<b>Year of Bar Admission</b>	<b>Hourly Rate</b>	<b>Hours</b>	<b>Total Compensation</b>
Thomas D. Berghman	Shareholder	2012	\$600	0.2	\$120.00
Garrick C. Smith	Shareholder	2013	\$520	51.5	\$26,780.00
Total Attorney Blended Rate			\$522.33		
<b>Total</b>				<b>51.7</b>	<b>\$ 26,900.00</b>

**EXHIBIT B**

**Summary of Legal Fees and Expenses by Category for the Fee Period**

<b>Task Description (Matter No.)</b>		<b>Total Hours</b>	<b>Total Fees Requested</b>
01	Asset Analysis, Disposition, Recovery	2.4	\$1,248.00
02	Assumption/Rejection of Leases and Contracts	2.0	\$1,040.00
03	Business Operations	0.0	\$0.00
04	Case Administration and General Strategy	2.3	\$1,212.00
05	Claims Administration and Objections	0.0	\$0.00
06	Court Hearings	2.4	\$1,248.00
07	Employment/Fee Applications	5.4	\$2,808.00
08	Expenses	0.0	\$0.00
09	Innovatus Investigation and Litigation	5.5	\$2,860.00
10	Litigation/Avoidance Actions: Contested Matters and Adversary Proceedings	0.0	\$0.00
11	Meetings and Communications with Debtors	0.0	\$0.00
12	Meetings and Communications with Committee	0.8	\$416.00
13	Meetings and Communications with Creditors	0.0	\$0.00
14	Non-Working Travel	0.0	\$0.00
15	Plan/Disclosure Statement	30.9	\$16,068.00
16	Schedules and Statements	0.0	\$0.00
<b>TOTAL</b>		<b>51.7</b>	<b>\$26,900.00</b>

<b>Category (Expense)</b>	<b>Total Fees Requested</b>
	\$0.00

**EXHIBIT C**

**Munsch Hardt Invoice**



DALLAS / HOUSTON / AUSTIN

Ross Tower  
500 N. Akard Street, Suite 4000  
Dallas, Texas 75201-6605  
Main 214.855.7500  
Fax 214.855.7584  
munsch.com

Unsecured Creditors Committee for Eiger  
BioPharmaceuticals, Inc.




Invoice Date: September 10, 2024  
Invoice Number: 10537279  
Matter Number: 023024.00001

*For Professional Services through August 31, 2024*

**Client:** Unsecured Creditors Committee for Eiger BioPharmaceuticals, Inc.  
**Matter:** Eiger BioPharmaceuticals

Total Fees	\$	<u>26,900.00</u>
<b>TOTAL THIS INVOICE</b>	<b>\$</b>	<b>26,900.00</b>
Previous Balance	\$	<u>9,567.30</u>
<b>Total Balance Due</b>	<b>\$</b>	<b>36,467.30</b>



**Remittance Address:**  
Accounting  
Munsch Hardt Kopf & Harr, P.C.  
500 N. Akard St., Suite 4000  
Dallas, TX 75201-6605

Include Client or Matter Number and Invoice Number with remittance.

Payments by credit card or eCheck: <https://www.munsch.com/payment>. A 2.5% service fee will be added to credit card payments.

**MH Federal ID Number:** 75-2096964

**For billing inquiries, please contact [accounting@munsch.com](mailto:accounting@munsch.com) or (214) 740-5198.**

Munsch Hardt Kopf & Harr, P.C.

Matter Number: 023024.00001

Invoice Number: 10537279

Client: Unsecured Creditors Committee for Eiger BioPharmaceuticals, Inc.

Matter Description: Eiger BioPharmaceuticals

2 of 8

September 10, 2024

**Fee Detail**

**Task Code:** 01 Asset Analysis, Disposition, Recovery

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/06/24	GCS	Review and analyze motion and proposed order for sale of the Lonafarnib and Lambda assets (.9); email correspondence with the Meland Budwick team regarding asset proceeds and recoveries from any remaining asset sales by the Debtors (.3).	1.20	624.00
08/14/24	GCS	Review disclosures, updates, and issues related to the sale of the Lonafarnib and Lambda (.4); review objection filed against the sale of assets (.5); review docket related to filings in support of the asset sale (.3).	1.20	624.00
<b>Total for 01</b>			<b>2.40</b>	<b>1,248.00</b>

**Task Code:** 02 Assumption/Rejection of Leases and Contracts

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/08/24	GCS	Review objections filed regarding assumption and cure of executory contracts and unexpired leases (.6); review schedule of proposed cure amounts for unsecured creditors (.2).	0.80	416.00
08/16/24	GCS	Review list of assumed executory contracts and unexpired leases and associated cure amounts (.5); email correspondence with Meland Budwick team related to same (.7).	1.20	624.00
<b>Total for 02</b>			<b>2.00</b>	<b>1,040.00</b>

**Task Code:** 04 Case Administration and General Strategy

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/05/24	GCS	Review notice of withdrawal of standing motion for affixing my signature (.5); email correspondence with counsel to debtors and equity committee regarding standing motion and related filings in the bankruptcy case (.2).	0.70	364.00
08/07/24	GCS	Review proposed protective order between the debtors and the equity committee for exchange of confidential information (.4); review case docket and updates for deadlines and issues for discussion with the Committee members (.3).	0.70	364.00
08/19/24	TDB	Correspondence with all counsel regarding SVB, cash collateral issues	0.20	120.00

Munsch Hardt Kopf & Harr, P.C.

Matter Number: 023024.00001

Invoice Number: 10537279

Client: Unsecured Creditors Committee for Eiger BioPharmaceuticals, Inc.

Matter Description: Eiger BioPharmaceuticals

3 of 8

September 10, 2024

08/26/24	GCS	Review docket and case filings regarding updates for upcoming hearings (.4); review correspondence with co-counsel and creditors related to same (.3).	0.70	364.00
<b>Total for 04</b>			<b>2.30</b>	<b>1,212.00</b>

**Task Code:** 06 Court Hearings

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/20/24	GCS	Attend hearing and hearing meetings regarding the sale of certain additional assets of the debtor as well as estimation of Innovatus's claim for escrow and reserve of potential amounts owed to Innovatus (2.4).	2.40	1,248.00
<b>Total for 06</b>			<b>2.40</b>	<b>1,248.00</b>

**Task Code:** 07 Employment/Fee Applications

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/07/24	GCS	Review draft invoice issues and coordinate for filing monthly fee statements pursuant to the interim compensation order (.5).	0.50	260.00
08/12/24	GCS	Draft Munsch Hardt monthly fee statement for July (.3); review Munsch Hardt invoice and final changes for preparing fee statement (.3); review and finalize Meland Budwick fee statement for June (.4); email correspondence with Meland Budwick team regarding filing monthly fee statement for June (.2); file Meland Budwick monthly fee statement (.3); file Munsch Hardt monthly fee statement in final form with exhibit (.3).	1.80	936.00
08/16/24	GCS	Email correspondence regarding confirmation of wire and bank information for coordinating payment of monthly invoices pursuant to interim compensation procedures (.3); email correspondence with Meland Budwick regarding same (.4).	0.70	364.00
08/19/24	GCS	Email correspondence with counsel to the Debtors regarding monthly fee statements and invoice payment (.4); review monthly fee statements for June and the docket for any potential objections to same for Meland Budwick and Munsch Hardt (.3).	0.70	364.00
08/22/24	GCS	Review any potential objections to July monthly fee statement (.2); confirm amounts and obligations for payment for July fees and expenses for Munsch Hardt and Meland Budwick (.6).	0.80	416.00



Munsch Hardt Kopf & Harr, P.C.

Matter Number: 023024.00001

Invoice Number: 10537279

Client: Unsecured Creditors Committee for Eiger BioPharmaceuticals, Inc.

Matter Description: Eiger BioPharmaceuticals

4 of 8

September 10, 2024

08/26/24	GCS	Email correspondence with Meland Budwick regarding July monthly fee statements (.3); review monthly fee statements and calculations of amounts owed for July (.4); email correspondence with counsel to the Debtors related to payment of same (.2).	0.90	468.00
<b>Total for 07</b>			<b>5.40</b>	<b>2,808.00</b>

**Task Code:** 09 Innovatus Investigation and Litigation

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/12/24	GCS	Email with Dan Gonzalez regarding conference call with debtors' counsel related to Innovatus litigation and claim objection (.1); review Innovatus claim issues related to potential objections and investigation (.4).	0.50	260.00
08/15/24	GCS	Review and analyze draft objection to the Innovatus claim and precedent related thereto (1.2); email correspondence with the Meland Budwick team related to same (.2).	1.40	728.00
08/19/24	GCS	Email correspondence with Meland Budwick regarding hearing for estimation of Innovatus claim and related filings for estimation of Innovatus claim (.3); review objection, pleadings, and exhibits related to Innovatus claim and litigation disputes (.8); analyze expert report in support of estimation of Innovatus claim (.6); review docket and agenda related to Innovatus claim estimation and determination (.2).	1.90	988.00
08/20/24	GCS	Review and analyze case filings regarding Innovatus's claim and objections related thereto for estimation of the claim (.6); conference with Dan Gonzalez related to same (.2).	0.80	416.00
08/23/24	GCS	Review order entered regarding estimation of the Innovatus claim for purposes of claim administration and litigation (.3); review issues raised by Meland Budwick team related to Innovatus claim (.6).	0.90	468.00
<b>Total for 09</b>			<b>5.50</b>	<b>2,860.00</b>

**Task Code:** 12 Meetings and Communications with Committee

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/05/24	GCS	Email correspondence with the members of the creditors committee regarding case updates and strategy, including the claim estimation for Innovatus, voting on the plan, and next steps prior to confirmation (.4).	0.40	208.00
08/23/24	GCS	Email correspondence with Meland Budwick and the members of the creditors committee regarding case updates, plan confirmation, and strategic considerations (.4).	0.40	208.00
<b>Total for 12</b>			<b>0.80</b>	<b>416.00</b>

**Task Code:** 15 Plan and Disclosure Statement

Munsch Hardt Kopf & Harr, P.C.

Matter Number: 023024.00001

Invoice Number: 10537279

Client: Unsecured Creditors Committee for Eiger BioPharmaceuticals, Inc.

Matter Description: Eiger BioPharmaceuticals

5 of 8

September 10, 2024

<u>Date</u>	<u>Initials</u>	<u>Description</u>	<u>Hours</u>	<u>Amount</u>
08/05/24	GCS	Analyze third party release issues and opt out structure in the Plan based on recent Fifth Circuit precedent (.8); review voting updates for schedule of unsecured creditor class (.3); email correspondence and analysis with Meland Budwick team regarding potential plan issues and objections for the unsecured creditors (.4); review plan administrator and liquidating trustee options under the plan (.1).	1.60	832.00
08/09/24	GCS	Review and analyze declaration and other filings in support of estimation of the Innovatus claim for reserve to make distributions to unsecured creditors under the proposed plan (.5); review docket and updates related to plan proposal (.6); analyze email correspondence with the debtors' counsel and Meland Budwick team related to liquidation analysis and plan administrator updates for the proposed plan (.3).	1.40	728.00
08/12/24	GCS	Conference call with Meland Budwick team regarding plan confirmation issues and updates from the debtors and equity committee (.6); research related to plan distribution and interest issues for unsecured creditors in the plan (1.5).	2.10	1,092.00
08/14/24	GCS	Review draft liquidating trust agreement shared by counsel to the debtors (1.1); email correspondence with Meland Budwick team and Debtor's counsel related to same (.2); conference call with counsel to the debtors, equity committee, and the creditors committee related to the proposed plan (.7); conference call with Dan Gonzalez related to Innovatus claim issues and strategy as it relates to payment and distributions to unsecured creditors (.3); review Innovatus claim issues and potential objections prior to conference call (.6).	2.90	1,508.00
08/15/24	GCS	Review and analyze draft liquidating trust agreement issues for payments to unsecured creditors as part of the plan supplement (1.3); review plan administrator agreement for potential comments to the draft (.5); research related to plan issues and potential objections if not resolved (1.0).	2.80	1,456.00
08/16/24	GCS	Revise Liquidation Trust Agreement in coordination with Meland Budwick team (.8); conference with Dan Gonzalez regarding proposed comments to the Liquidation Trust Agreement (.5); Analyze expert report and objections filed by Innovatus regarding estimation and reserve for claim for purposes of Plan confirmation and distributions (.8); analyze case filings in support of Innovatus claim estimation for purposes of plan treatment and distributions (.6); email correspondence with Meland Budwick regarding same (.4); review declarations filed in support of plan treatment and estimation of claims for Innovatus (.4).	3.50	1,820.00
08/17/24	GCS	Email correspondence with Meland Budwick team and the committee regarding objecting to the liquidation trust agreement (.2); review additional issues and questions regarding the liquidating trust agreement, costs of liquidating professionals, and timing for distributions to unsecured creditors under the proposed plan and trust agreement (.9).	1.10	572.00

Munsch Hardt Kopf & Harr, P.C.

Matter Number: 023024.00001

Invoice Number: 10537279

Client: Unsecured Creditors Committee for Eiger BioPharmaceuticals, Inc.

Matter Description: Eiger BioPharmaceuticals

6 of 8

September 10, 2024

08/19/24	GCS	Research related to plan and distribution to general unsecured creditors (.6); review email correspondence with Meland Budwick related to plan issues and distribution mechanics (.2).	0.80	416.00
08/20/24	GCS	Conference with Dan Gonzalez related to plan and confirmation issues for the creditors committee (.4); review plan issues and research related to same (.5).	0.90	468.00
08/21/24	GCS	Review plan issues and updates regarding payment in full for unsecured creditors (.8); review email correspondence related to same (.4).	1.20	624.00
08/23/24	GCS	Email correspondence with Meland Budwick team and Debtors' counsel regarding the plan administrator and liquidation analysis associated with plan confirmation (.2); research and review related to potential plan objections and liquidation analysis and plan administrator issues (1.1).	1.30	676.00
08/26/24	GCS	Review correspondence with Meland Budwick related to plan confirmation updates and issues (.3); analyze plan issues and updates for the confirmation hearing (.5).	0.80	416.00
08/27/24	GCS	Conference call with Dan Gonzalez regarding plan confirmation and potential questions related to same for counsel to the Debtors (.4); review and analyze plan issues for discussion with counsel to the Debtors (1.0); review docket updates related to plan deadlines and potential plan treatment issues (.4).	1.80	936.00
08/28/24	GCS	Analyze confirmation brief in support of plan confirmation and releases (.9); research related to potential objections regarding impairment, releases, and claim allowance (1.2); review docket filings and updates for plan confirmation issues (.5).	2.60	1,352.00
08/29/24	GCS	Review and analyze confirmation brief and plan confirmation issues (.6); review email correspondence with Meland Budwick regarding plan issues and confirmation hearing (.2).	0.80	416.00
08/30/24	GCS	Review and analyze objection filed by Innovatus related to confirmation of the Plan (.8); review and analyze objection filed by the equity committee (.9); review and analyze objection filed by the U.S. Trustee (.5); research related to confirmation objections and issues for impairment and releases (.7); correspondence with Meland Budwick team regarding plan and confirmation hearing issues (.4); review redline of plan related to same (.1).	3.40	1,768.00





Ross Tower  
500 N. Akard Street, Suite 4000  
Dallas, Texas 75201-6605  
Main 214.855.7500  
Fax 214.855.7584  
munsch.com

Unsecured Creditors Committee for Eiger  
BioPharmaceuticals, Inc.



Invoice Date: September 10, 2024  
Invoice Number: 10537279  
Matter Number: 023024.00001

*For Professional Services through August 31, 2024*

**Client:** Unsecured Creditors Committee for Eiger BioPharmaceuticals, Inc.  
**Matter:** Eiger BioPharmaceuticals

Total Fees	\$	<u>26,900.00</u>
<b>TOTAL THIS INVOICE</b>	<b>\$</b>	<b>26,900.00</b>
Previous Balance	\$	<u>9,567.30</u>
<b>Total Balance Due</b>	<b>\$</b>	<b>36,467.30</b>



**Remittance Address:**  
Accounting  
Munsch Hardt Kopf & Harr, P.C.  
500 N. Akard St., Suite 4000  
Dallas, TX 75201-6605

Include Client or Matter Number and Invoice Number with remittance.

Payments by credit card or eCheck: <https://www.munsch.com/payment>. A 2.5% service fee will be added to credit card payments.

**MH Federal ID Number:** 75-2096964

**For billing inquiries, please contact [accounting@munsch.com](mailto:accounting@munsch.com) or (214) 740-5198.**